한국어
Quantus

GL Pharm Tech

204840 · KOSDAQ
₩5,300+0.38%
2026-09-04 close

GL Pharm Tech last closed at ₩5,300 (+0.38%) on 2026-09-04. Listed on KOSDAQ; price, financials and dividends update daily after market close.

Loading chart…
Close
No active signal.

New high + volume — the real recordrecord · not a prediction

Last 30 sessions
303 picks
Next-day win rate
50.7%
Avg next-day
-0.11%
vs market
-0.49%p

Every new-high-plus-volume pick we actually published (Korea market) — not this stock alone.

Trade plan

Fill entry, stop, account size and risk percent to get a share count. The stop must sit below the entry.

A calculator · not advice or a guarantee

Financials & valuation at a glance

D
Overall: 건강관리 237/291 · top 81%
Factor composite · relative position in sector

PER — · PBR 4.16 — own-history percentile 62/100 · 67/100

Open self-history band
PER62/100
PBR67/100

Factual information · not investment advice

Past reported results · not investment advice

More — deeper indicators

Financial safety

Reference indicatorAs of 2024
Distress zoneFinancial-metric reference signal
Altman Z'' zoneZ'' -0.28
Distress
Grey
Safe
The marker shows the current Z'' value within the displayed zones.
Altman Z''
-0.28
Beneish M-Score
-2.19

No statistical flag

Sloan accrual
5.44%

부실·조작 위험을 나타내는 사실 지표입니다. 투자 조언이 아니며, 검증 전이라 참고용입니다.

Factual information, not investment advice.

Earnings quality · Piotroski F-Score

5/9Moderate

Piotroski measures year-over-year financial improvement, not absolute quality.

Financial improvement score5/9

Profitability

  • Positive ROANot passed
  • Positive OCFNot passed
  • Improving ΔROAPass
  • Accruals (OCF > net income)Not passed

Leverage & liquidity

  • Lower debtPass
  • Higher current ratioPass
  • No new sharesPass

Efficiency

  • Higher gross marginPass
  • Higher asset turnoverNot passed

Calculation note: F7(신주)은 equity/asset 유지로 근사

Already-stable companies may score lower when year-over-year improvement is limited.

Factual information, not investment advice.

Forensic signals

Anomaly and structural signals observed in the financial statements.

Revenue qualityDanger

매출 흑자인데 영업CF 적자 (OCF/매출 -18%). 통계적 정황 신호이며 회계부정 단정이 아닙니다.

Factual information, not investment advice.

Industry structure

KRAs of 2026-09-05

건강관리

This stock is in 건강관리: revenue rank 197 of 287, share 0%.

197 / 2870%revenue share

Who dominates this industry?

  1. 1삼성바이오로직스7.3%
  2. 2셀트리온5.7%
  3. 3녹십자홀딩스3.5%
  4. 4유한양행3.3%
  5. 5대웅3.1%
  6. 6지엘팜텍0%

Concentration

DistributedCR3 16.6%
HHI 202287 revenue members

HHI and CR3 are separate industrial-organization facts; they are not the polarization verdict.

Polarization

Winner-take-all deepeningConsistent

Polarization measures industry gaps and structure, not valuation, forecast, or investment advice.

Margin lens

IQR%p
31.61
Direction
확대
Level
넓음
Years
7

Value lens

P90/P10
13.9
Median P/B
1.47
Level
넓음
n
263

Survivorship note: 현재 산업 멤버십을 과거 연도에 소급 적용 — 과거 진입·퇴출 기업 미반영(복원 불가)

Factual information, not investment advice.

Risk sensitivity — adverse assumptions

Metric changes under stated assumptions; not a forecast or investment advice.

Base metrics

Operating margin
-6.8%
Interest coverage
-2.3x
Return on equity (ROE)
-11.9%

Operating margin −5pp

Operating loss
Interest coverageBase -2.3x adverse case -4x
Return on equity (ROE)Base -11.9% adverse case -19.5%

Revenue −15%

Interest coverage risk
Interest coverageBase -2.3x adverse case -2x
Return on equity (ROE)Base -11.9% adverse case -11.6%

Interest rate +2pp

Interest coverage risk
Interest coverageBase -2.3x adverse case -1.4x
Return on equity (ROE)Base -11.9% adverse case -15.2%

Interest coverage limit

Already below the limit by 9.7pp

Interest coverage limit at an operating margin of 3%

Interest expense coverage threshold

Who held it · filings

Filed record

A historical record from curated-guru 13F filings and DART 5%+ major-holding disclosures.

US 13F는 분기 공시이며 최대 45일 뒤 제출될 수 있습니다.

5%+ major-holding disclosures

  • 더블유사이언스29.81%2026-08-06 · 증감 +0.03%p

Connections

AI-extracted related companies · for reference

🔗 See in the full market map →

Recent filings

GL Pharm Tech's latest filings on Korea's DART. Open a headline for a reference summary and the original.

Source: DART (Korea electronic disclosure)

About GL Pharm Tech
What technical signals does GL Pharm Tech (204840) have?
GL Pharm Tech current technical signals: no active technical signal.
Is GL Pharm Tech a cup-and-handle pattern?
No. GL Pharm Tech has no valid cup-and-handle signal right now.
What are GL Pharm Tech's financials and valuation?
GL Pharm Tech's income statement, balance sheet and cash flow are free for the most recent 8 years; the full history is on Pro. PER/PBR, dividend yield and sector valuation bands are free.

Like these rules? Backtest them.

Run this signal on this ticker in the free backtest builder — same window, no install.

Backtest this rule ↗

Quantus Signal · live data · not investment advice · Privacy Policy